admin

It’s taken 30 years and more than $565 million to make it happen: the first-ever malaria vaccine. The innoculation, called Mosquirix, is the first of its kind to fight a parasite and has the potential to transform the lives of millions of people living in malaria-stricken areas. An estimated half million people die from the disease every year, the majority children. Such deaths have fallen by 47% since 2000 thanks to better prevention methods, but many have been waiting a long time for a vaccine that could protect children better and earlier.

Headquartered in Pasadena, California, Alexandria Real Estate Equities (ARE) was founded by Joel S. Marcus and Jerry M. Sudarsky in 1994. The company is structured as a REIT (real estate investment trust) and completed an initial public offering in 1997. The company is now the third-largest publicly traded office REIT in the United States and is part of the S&P 400.

Chief Scientific Officer Prof Dolores Schendel appointed new Chief Executive Officer of Medigene AG

Dave Lemus appointed Chief Operating Officer of Medigene AG and Chief Executive Officer of Medigene Inc. in the United States

Martinsried/Munich, 17 December 2015. Medigene AG (Frankfurt Stock Exchange: MDG1) announced today that the Supervisory Board has resolved important changes and additions to the senior management team to better align the organisational structure with the strategic goals of the company in immuno-oncology and to expand Medigene’s presence in the United States.

Drs. Donald Zack and Valentin Sluch spent 30 anxious days waiting for their experiment to yield results.

They were eager to see if the retinal ganglion cells growing in their lab would turn red, indicating that they’d successfully edited the cells’ DNA. Turning the eye cells red would allow them to be sorted from other cells and potentially provide the key to research that one day could lead to a cure for blindness caused by glaucoma or multiple sclerosis.

Brace Pharma Capital led a $33 million Series B funding in Navitor Pharmaceuticals, a biopharmaceutical company. Other investors in the funding included Remeditex Ventures, Sanofi-Genzyme BioVentures and an undisclosed individual investor. Existing investors Polaris Partners, Atlas Venture, Johnson & Johnson Innovation and SR One also participated. Vinzenz Ploerer, president and chief executive officer of Brace Pharma Capital, will join Navitor’s board.

May 8 – 11, 2016

ANNOUNCING NOMINATIONS NEW BEING ACCEPTED FOR THE HEALTH DATA LIBERATORS AWARD

The Datapalooza’s Health Data Liberators Award recognizes extraordinary contributions and leadership in the liberation of health data, helping to accelerate the pace and multiply the volume of data available to innovators in order to foster the creation of products and services to improve health and health care. The Award is presented annually and will be bestowed to the recipient at 2016 Health Datapalooza in Washington, DC.

It’s hard to get people to eat right.

Healthy food can be expensive and time consuming to prepare.

Pharmaceutical group GlaxoSmithKline said its majority-owned HIV business would buy drugs at different stages of development from U.S. rival Bristol-Myers Squibb for an initial $350 million.

GSK said the acquisitions would provide ViiV Healthcare, its HIV unit in which Pfizer and Shionogi are junior partners, with new opportunities for growth.

AstraZeneca along with MedImmune, its global biologics research and development arm, announced a range of strategic initiatives to accelerate the delivery of innovative biologics and targeted medicines to patients in China, the company’s second largest market globally and a key growth platform.

The initiatives and investments include a strategic alliance with WuXi AppTec, a leading Chinese biologics manufacturer and contract research organisation, to produce innovative biologics locally in China. Under the agreement, AstraZeneca has the option to acquire WuXi AppTec’s biologics manufacturing capacity in Wuxi City in the next few years through an overall investment approximating $100 million. Prior to that, Wuxi AppTec remains the company’s exclusive partner for R&D manufacturing for innovative biologics in China.